HER2阳性乳腺癌患者皮下注射和静脉注射曲妥珠单抗的费用。
Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
作者信息
Olsen Jens, Jensen Kenneth Forsstrøm, Olesen Daniel Sloth, Knoop Ann
机构信息
Health Economics Department, Incentive, Holte Stationsvej 14, 1st, DK-2840 Holte, Denmark.
Pharmaceuticals Division, Roche Denmark, Industriholmen 59, DK-2650 Hvidovre, Denmark.
出版信息
J Comp Eff Res. 2018 May;7(5):411-419. doi: 10.2217/cer-2017-0048. Epub 2017 Dec 4.
AIM
Trastuzumab is available in an intravenous (iv.) and a subcutaneous (sc.) formulation. The objective of this study was to estimate the costs of administration of iv. and sc. trastuzumab treatment.
MATERIALS & METHODS: Via interviews, we identified all the activities associated with iv. and sc. administration. The outcome was time estimates. To estimate the administration costs, the time estimates were valued by average gross wages.
RESULTS
The iv. administration takes longer time as infusion time is longer (25 or 85 min). The iv. administration is associated with higher cost for 17 cycles; €971 (€1858 vs €887).
CONCLUSION
sc. administration is associated with lower administration costs. Switching patients from iv. to sc. would make it possible to treat more patients without increasing the personnel resources.
目的
曲妥珠单抗有静脉注射（iv.）和皮下注射（sc.）两种剂型。本研究的目的是估算静脉注射和皮下注射曲妥珠单抗治疗的给药成本。
材料与方法
通过访谈，我们确定了与静脉注射和皮下注射相关的所有活动。结果是时间估算值。为估算给药成本，时间估算值按平均总工资进行估值。
结果
由于输注时间较长（25或85分钟），静脉注射耗时更长。静脉注射17个周期的成本更高；971欧元（1858欧元对887欧元）。
结论
皮下注射的给药成本较低。将患者从静脉注射改为皮下注射将有可能在不增加人力资源的情况下治疗更多患者。
Zotero 插件